340 related articles for article (PubMed ID: 29690851)
1. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Dülgeroglu J; Schmidt D
Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
[No Abstract] [Full Text] [Related]
2. [Not Available].
Simeon L; Wuillemin WA
Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
[No Abstract] [Full Text] [Related]
3. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
Robert-Ebadi H; Righini M
Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
[No Abstract] [Full Text] [Related]
4. [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?].
Buerke M; Hoffmeister HM
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):105-110. PubMed ID: 28074293
[TBL] [Abstract][Full Text] [Related]
5. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Pollack CV
Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
[No Abstract] [Full Text] [Related]
6. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
7. [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Mohebbi N
Praxis (Bern 1994); 2018 Jun; 107(13):683-687. PubMed ID: 29921184
[TBL] [Abstract][Full Text] [Related]
8. [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Gulba DC; Broscaru L
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):83-91. PubMed ID: 28144727
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
10. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring of NOAC].
Zotz RB; Weißbach L
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):92-98. PubMed ID: 28083625
[TBL] [Abstract][Full Text] [Related]
12. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Ruff CT; Giugliano RP; Antman EM
Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh EA; Chalmers L; Bereznicki LR
Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
[TBL] [Abstract][Full Text] [Related]
14. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Oberhofer E
MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
[No Abstract] [Full Text] [Related]
15. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G
Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471
[No Abstract] [Full Text] [Related]
16. [State of the art: Direct oral anticoagulants and transfusion].
Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM
Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500
[TBL] [Abstract][Full Text] [Related]
17. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Grandone E; Aucella F; Barcellona D; Brunori G; Forneris G; Gresele P; Marietta M; Poli D; Testa S; Tripodi A; Genovesi SC
Blood Transfus; 2020 Nov; 18(6):478-485. PubMed ID: 33000751
[TBL] [Abstract][Full Text] [Related]
18. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
19. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Pan EY; Sobieraj DM
Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
[No Abstract] [Full Text] [Related]
20. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
